By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
Haemonetics showed strong fiscal 2026 results but FY2027 guidance is conservative. The company faces risks from Interventional Technologies, PerQseal Elite's FDA uncertainty, and potential headwinds in hospital procedure volumes. Despite a 'FCF fortress', there are concerns about optionality cost and the sustainability of high-teens hemostasis growth.
Risk: Interventional Technologies remaining a headwind and PerQseal Elite's FDA uncertainty
Opportunity: Strong free cash flow and potential margin leverage if Plasma surprises
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Haemonetics reported fiscal Q4 revenue of $346 million, up 5% reported and 9% organically excluding CSL, with adjusted EPS of $1.29. For the full year, revenue reached $1.3 billion and adjusted EPS was $4.96, helped by stronger margins and free cash flow.
Plasma and Blood Management Technologies were the main growth drivers, while Interventional Technologies remained weak. Plasma grew 13% organically in the quarter, and Blood Management Technologies posted a record quarter, but Interventional Technologies revenue fell 10% due to softness in vascular closure and related procedures.
Fiscal 2027 guidance calls for reported revenue growth of 4% to 7% and adjusted operating margin expansion of 50 to 100 basis points. The company also said it expects continued momentum from Plasma, modest Hospital growth, and no revenue contribution yet from PerQseal Elite while it awaits FDA review.
Haemonetics (NYSE:HAE) reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies businesses offset continued pressure in Interventional Technologies.
President and CEO Christopher Simon said the company delivered adjusted earnings of $1.29 per share in the quarter, up 4% from a year earlier. For fiscal 2026, Haemonetics reported revenue of $1.3 billion and adjusted earnings of $4.96 per share, with Simon citing higher adjusted margins and stronger free cash flow despite $153 million of non-recurring revenue impacts from portfolio transitions.
“Our performance reflects the strength of our core platforms, with Plasma and TEG driving momentum, margin expansion, and reinforcing our leadership in attractive end markets,” Simon said.
Plasma Growth Leads Core Momentum
Plasma revenue was $130 million in the fourth quarter, up 3% reported and 13% organically excluding CSL, as Haemonetics annualized the final effects of the discontinued CSL U.S. disposable supply agreement. Full-year Plasma revenue was $524 million, down 2% reported but up 20% organically excluding CSL, above the company’s revised guidance range of 17% to 19%.
Simon said Plasma benefited from market fundamentals including resilient immunoglobulin demand and expansion in global plasma collections. He said Haemonetics’ share of U.S. plasma collections grew in the high single digits in both the quarter and the full year, while Europe posted double-digit growth.
The company also highlighted U.S. Food and Drug Administration clearance of Persona PLUS, which Simon described as the next step in Haemonetics’ plasma innovation cycle. He said the product improves yield by a mid-single-digit percentage on average and has generated “strong customer enthusiasm,” with multiple adoptions underway.
During the question-and-answer portion of the call, Simon said fiscal 2026 was a record year for Plasma, supported by price from the Persona rollout, share gains and a return to double-digit collection volume growth in the latter part of the year. For fiscal 2027, he said the company’s guidance assumes only 0% to 2% collection volume growth, leaving potential upside if collection trends remain strong or Persona PLUS adoption accelerates.
Hospital Business Mixed as TEG Strength Offsets IVT Weakness
Hospital revenue was $160 million in the fourth quarter and $588 million for the full year, growing 8% in the quarter and 4% for the year. On an organic basis, Hospital revenue rose 7% in the quarter and 4% for the year.
Blood Management Technologies delivered what Simon called a record quarter, with revenue up 21% in the quarter and 14% for the year. Hemostasis management grew in the high teens, driven by TEG 6s strength, higher disposable utilization, capital placements and momentum in Europe following the HN cartridge launch. Transfusion management also contributed meaningfully, accounting for nearly half of franchise growth in the quarter.
Interventional Technologies remained a drag, with revenue declining 10% in the quarter and 9% for the full year. Vascular closure revenue fell 8% in the quarter, reflecting a 6% decline in MVP and MVP XL in electrophysiology and continued softness in coronary and peripheral procedures. Simon said performance in electrophysiology was affected by share loss early in fiscal 2026 and shifting procedure dynamics.
However, Simon said the company has “renewed confidence” in the trajectory of Interventional Technologies. He said two headwinds that drove about 80% of the fiscal 2026 decline — OEM-related softness in sensor-guided technologies and the impact of pulsed-field ablation on esophageal cooling — have either been lapped or reduced to a non-material base.
In response to an analyst question, Simon said the fourth quarter could later be viewed as the point when Haemonetics’ Interventional Technologies business “turned the corner,” citing a stronger commercial organization, better tools, improved products and a more favorable market backdrop.
Margins Expand for the Full Year, Cash Flow Improves
EVP and CFO James D’Arecca said adjusted gross margin in the fourth quarter was 59.7%, down 50 basis points from a year earlier. The decline reflected the absence of a prior-year CSL shortfall payment and tariff impacts, partly offset by a higher-margin portfolio.
For the full year, adjusted gross margin expanded 280 basis points to 60.3%, driven by portfolio transformation, volume growth in Plasma and Blood Management Technologies, and demand for the company’s products. Adjusted operating margin expanded 140 basis points for the year to 25.4%.
Fourth-quarter adjusted operating expenses were $122 million, up 5% year-over-year. D’Arecca attributed the increase to the Vivasure acquisition, tariffs, higher self-insured benefits costs, higher performance-based compensation and targeted commercial investments.
Free cash flow was $45 million in the fourth quarter and $210 million for the full year, with a free cash flow to adjusted net income conversion ratio of 89%. D’Arecca said full-year free cash flow increased by $65 million, largely due to working capital improvement and lower capital expenditures.
Haemonetics ended the year with $245 million in cash after repurchasing more than 3 million shares for $175 million and investing $61 million in the Vivasure acquisition. Total debt remained $1.2 billion, and the company reported a net leverage ratio of 2.73 times EBITDA as defined in its credit agreement.
Fiscal 2027 Guidance Calls for Revenue and Margin Growth
Haemonetics issued fiscal 2027 guidance calling for reported revenue growth of 4% to 7% and organic revenue growth of 3% to 6%, adjusted for foreign exchange and the 53rd week.
By segment, Simon said the company expects:
Hospital revenue to grow in the mid-single digits, with contributions from both Blood Management Technologies and Interventional Technologies.
Plasma revenue to grow in the mid-single digits, supported by share gains, Persona PLUS rollout and modest collection volume growth.
Blood Center revenue to decline in the mid-single digits due to ongoing portfolio rationalization, despite support from plasma-driven demand and customer relationships.
D’Arecca said adjusted operating margin is expected to improve 50 to 100 basis points in fiscal 2027, driven by growth franchises, innovation and operating leverage. The outlook includes a full year of dilution from Vivasure with no revenue contribution assumed, additional tariff impacts, ERP-related costs and continued targeted investments.
Adjusted EPS is expected to grow broadly in line with reported revenue, with operating leverage and mix benefits offset by higher interest and tax expense. D’Arecca said the company expects free cash flow conversion of approximately 80%, reflecting working capital discipline and flexibility to invest in growth, reduce leverage and pursue opportunistic share repurchases.
PerQseal Elite Not Included in Revenue Outlook
Haemonetics said its fiscal 2027 guidance does not include revenue from PerQseal Elite, the large-bore vascular closure product acquired through Vivasure, which is currently under FDA review. Simon said the company has included launch expenses in its guidance but excluded sales because the timing of clearance remains uncertain.
“Whenever it comes, we will be ready to go,” Simon said, adding that the product could strengthen Haemonetics’ position in vascular closure and structural heart.
Simon closed the call by saying fiscal 2026 marked the culmination of the company’s long-range transformation plan. He said Haemonetics is now a more focused company with a higher-quality portfolio, stronger margins and better cash flow, and that its fiscal 2027 priorities are to continue winning in Plasma, extend its leadership in TEG and reinvigorate growth in vascular closure.
About Haemonetics (NYSE:HAE)
Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.
The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Four leading AI models discuss this article
"Haemonetics has successfully stabilized its core margins, but the stock's next leg up depends entirely on the binary outcome of the PerQseal Elite FDA approval rather than organic growth in its legacy segments."
HAE is successfully transitioning from a commodity-heavy blood equipment player to a higher-margin, technology-driven medtech firm. The 20% organic growth in Plasma (ex-CSL) and 280 bps gross margin expansion signal that the portfolio rationalization is working. However, the market is pricing in a 'turnaround' for the Interventional Technologies (IVT) segment that remains speculative. While management claims they have 'lapped' the headwinds, a 10% revenue decline in IVT is a significant drag. With fiscal 2027 EPS growth pegged only to revenue growth, the stock lacks a major near-term catalyst until PerQseal Elite gains FDA approval, making the current valuation sensitive to any further execution slips in the hospital segment.
The guidance for 0-2% plasma collection growth is overly conservative, but if the broader plasma market faces a cyclical downturn, HAE's reliance on this segment could lead to a significant multiple compression.
"HAE's FY27 guidance embeds conservatism on Plasma volumes and excludes PerQseal upside, positioning for revenue beats and margin leverage if core momentum sustains."
HAE's FY26 delivered standout Plasma organic growth of 20% ex-CSL (13% in Q4), record Blood Management (21% Q4, 14% FY) led by TEG 6s high-teens hemostasis surge, and 280bps gross margin expansion to 60.3% fueling $210M FCF (89% conversion). FY27 guide of 4-7% revenue, mid-single digit segment growth, and 50-100bps op margin gain is conservative—assumes Plasma 0-2% volume growth vs. recent double-digits, no PerQseal revenue despite FDA review, and Blood Center mid-single decline. TEG Europe momentum, Persona PLUS yield boost (mid-single digits), and Interventional 'inflection' (lapping 80% headwinds) set up beats and re-rating.
Interventional Technologies' 10% Q4 decline and 9% FY drop signal persistent weakness if electrophysiology share losses or procedure softness endure beyond lapped headwinds. Vivasure dilution, tariffs, and no PerQseal contribution cap margins despite leverage.
"HAE's guidance assumes material plasma volume deceleration and vascular closure stabilization—both unproven—leaving limited margin of safety despite legitimate operational improvements."
HAE's fiscal 2026 results show real operational progress—Plasma organic growth of 20%, TEG record quarter, 280bps gross margin expansion—but FY2027 guidance is deliberately conservative. Management guides 4-7% reported growth after a 5% reported year, and assumes 0-2% plasma collection volume growth despite claiming Q4 returned to double-digit volumes. The 50-100bps margin expansion outlook is modest given the portfolio quality improvement already achieved. Most critically: Interventional Technologies (vascular closure) remains a 9% headwind, and management's "turned the corner" claim rests on lapping two specific headwinds—not on proven demand recovery. PerQseal Elite, a potential growth catalyst, contributes zero to guidance due to FDA uncertainty.
If plasma collection volume growth actually stalls (not accelerates), and vascular closure doesn't recover as expected, the company has guided itself into a corner with limited upside and execution risk on two fronts simultaneously.
"Haemonetics' 2027 upside depends on uncertain plasma collection growth and the timely commercialization of PerQseal Elite; without stronger, near-term catalysts, the 4–7% revenue growth and 50–100 bp margin expansion look fragile."
Haemonetics shows solid quarterly momentum driven by Plasma and Blood Management, with margin expansion and strong free cash flow. However, the 2027 guide hinges on modest mid-single-digit revenue growth and only 50–100 bps of margin expansion, while 0–2% expected collection growth leaves little room for upside if Plasma demand or Persona PLUS adoption slows. Interventional Technologies remains a headwind, PerQseal Elite is excluded from revenue, and risks from tariffs, ERP costs, and Vivasure dilution could weigh on profitability. Regulatory timing and cyclical hospital volumes add downside risk to the bull case embedded in the guidance.
The core bull case rests on uncertain drivers (Persona PLUS, collection volumes) delivering outsized upside; any delay in PerQseal Elite clearance or a slowdown in plasma collection could erode the thesis quickly.
"The combination of high debt service costs from the Vivasure acquisition and potential hospital capital expenditure pullbacks makes the current margin guidance overly optimistic."
Grok, your optimism on TEG 6s and Persona PLUS ignores the macro-sensitivity of hospital capital budgets. If hospital procedure volumes soften, as Claude hints, that high-teens growth in hemostasis is unsustainable. Furthermore, nobody has addressed the balance sheet impact of the Vivasure acquisition; with rising interest rates, the cost of servicing that debt while waiting for PerQseal Elite approval creates a margin squeeze that the current 50-100bps expansion target fails to fully insulate against.
"HAE's $210M FCF generation neutralizes Vivasure debt risks and unlocks buyback/PerQseal upside beyond the conservative guide."
Gemini, your Vivasure debt worry ignores the $210M FCF fortress (89% conversion rate)—more than enough to service acquisition debt even at elevated rates, while funding PerQseal ramp or buybacks. This cash machine de-risks the conservative FY27 guide far more than Interventional drags, enabling margin leverage to 62%+ if Plasma surprises. Panel fixates on revenue headwinds but misses FCF-fueled optionality.
"FCF fortress de-risks solvency but not the strategic timing conflict between PerQseal ramp, debt service, and hospital cycle softness."
Grok's FCF fortress argument is mechanically sound—$210M at 89% conversion does service Vivasure debt comfortably. But Gemini's real concern isn't solvency; it's *optionality cost*. If PerQseal Elite clears in late 2027, HAE must choose: fund ramp capex, service debt, or return cash. Hospital capex cycles are already tightening (Gemini's macro point stands). FCF strength doesn't eliminate the timing squeeze—it just delays when management has to choose between growth and shareholder returns.
"HAE's 'FCF fortress' is conditional; a slower plasma cycle or delayed PerQseal Elite could squeeze cash flow and capex choices, undermining the bull-case margin expansion."
Grok, your 'FCF fortress' rests on an optimistic Plasma tailwind and aggressive leverage; a best-case scenario, not a given. If Plasma growth stays at 0-2% and PerQseal Elite slips past 2027, HAE may have to divert cash to growth capex or debt service, squeezing FCF. The 62%+ margin path also hinges on both continued Plasma upside and IVT stabilization—fragile if hospital volumes falter or regulatory timing worsens.
Haemonetics showed strong fiscal 2026 results but FY2027 guidance is conservative. The company faces risks from Interventional Technologies, PerQseal Elite's FDA uncertainty, and potential headwinds in hospital procedure volumes. Despite a 'FCF fortress', there are concerns about optionality cost and the sustainability of high-teens hemostasis growth.
Strong free cash flow and potential margin leverage if Plasma surprises
Interventional Technologies remaining a headwind and PerQseal Elite's FDA uncertainty